



Integra LifeSciences Announces Launch of New Surgical Spine Instruments

PLAINSBORO, N.J., Sept. 15, 2010 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (Nasdaq:IART) announced the introduction of a new line of extended length and "detachable" Ruggles™ kerrison rongeurs, which are key instruments used in a variety of neuro and spine surgeries.

The Ruggles™ kerrison rongeurs with a detachable feature received 510(k) clearance from the United States Food and Drug Administration (FDA). The new feature allows for easier cleaning, and special coatings help preserve the instrument's sharpness.

Integra is also introducing an extended length kerrison to address the challenges of patients with increasing body mass index. With both detachable and extended length kerrison rongeurs, Integra expands what is already the broadest neuro instrument portfolio in the industry.

"These additions to our neuro/spine portfolio will limit the uncertainty of our customers, by making cleaning simpler and helping to ensure that they have the right instruments for each surgical procedure," said Dan Reuvers, President, Integra Surgical.

Integra Surgical is a leading provider of surgical instruments used in general surgery, neurosurgery, cardiac surgery and most other surgical modalities. The company also produces JARIT® general instruments, Omni-Tract® family of retractor systems and LUXTEC® illumination products. Please visit www.integrasurgical.com for more information.

[Integra LifeSciences Holdings Corporation](#), a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Integra's products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. Please visit www.integralife.com for more information.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use JARIT® brand surgical instruments, LUXTEC® illumination products, and Omni-Tract® retractor systems may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella, Director of Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.